Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data

PURPOSE: Second-line treatment with ramucirumab-paclitaxel has demonstrated statistically significant and clinically meaningful survival outcomes compared to paclitaxel-alone in patients with advanced gastric cancer (HR=0.807, 95% CI 0.678–0.962; P=0.017). Post hoc, exploratory analyses of RAINBOW p...

Descripción completa

Detalles Bibliográficos
Autores principales: Muro, Kei, Jen, Min-Hua, Cheng, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433106/
https://www.ncbi.nlm.nih.gov/pubmed/30962715
http://dx.doi.org/10.2147/CMAR.S193739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433106/
https://www.ncbi.nlm.nih.gov/pubmed/30962715
http://dx.doi.org/10.2147/CMAR.S193739

Ejemplares similares